FiercePharma

Boehringer Ingelheim's Ofev nabs FDA nod for expanded use in rare lung disease

Boehringer Ingelheim cast a wide net with its clinical program for pulmonary fibrosis med Ofev, hoping to carve out a sales niche in a huge range of ultrarare lung diseases. Already sporting an FDA ...
FiercePharma

We have a winner: Boehringer Ingelheim’s Ofev takes #FierceMadness ad championship

In a back-and-forth final matchup, Boehringer Ingelheim’s ad campaign for Ofev pulled away from GlaxoSmithKline’s Trelegy to land the #FierceMadness ad tournament crown. By a vote of 4,225-2,181, the ...
Business Insider

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

RIDGEFIELD, Conn., Sept. 17, 2018 /PRNewswire/ -- Results from INPULSIS-ON, published today in Lancet Respiratory Medicine, provide insights into the long-term safety, efficacy and tolerability of ...
Monthly Prescribing Reference

Ofev Approved for Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype

The FDA has approved Ofev (nintedanib; Boehringer Ingelheim) for the treatment of patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. The Food and Drug ...
Business Insider

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

RIDGEFIELD, Conn., May 14, 2021 /PRNewswire/ -- Boehringer Ingelheim today announced results from an analysis of the SENSCIS®-ON trial. SENSCIS-ON is an open-label extension trial of the Phase III ...
WLNS.com

U.S. FDA accepts supplemental New Drug Application for OFEV® (nintedanib) for children and adolescents aged 6-17 years old with fibrosing interstitial lung disease

RIDGEFIELD, Conn. and INGELHEIM, Germany, July 25, 2023 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug ...